

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000572

International filing date: 17 February 2005 (17.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0403491.4
Filing date: 17 February 2004 (17.02.2004)

Date of receipt at the International Bureau: 16 March 2005 (16.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

8 March 2005






18FEB04 E874048-2 000060
P01/7700 0.00-0403491.4 NONE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

NRS/CP6200364

2. Patent application number

(The Patent Office will fill this part in)

17 FEB 2004

0403491.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Cambridge University Technical Services Ltd
The Old Schools
Trinity Lane
Cambridge CB2 1TS
UNITED KINGDOM

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UK

6756809 004

4. Title of the invention

POLYPEPTIDES, METHODS AND MEANS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	46 ✓
Claim(s)	5 ✓
Abstract	0
Drawing(s)	15 + 15

Amc

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

N Sutcliffe

Date 16 February 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

NICHOLAS R SUTCLIFFE

020 7240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Polypeptides, Methods and Means

This invention relates to protein ligands which interact with the cell surface receptor NKG2D and the viral ligand
5 UL16.

The C-type lectin-like receptor NKG2D has a number of defined, MHC class I-related ligands in both mouse and man. Murine ligands include the retinoic acid early
10 transcript 1 (Rae-1) family, the minor histocompatibility antigen H60, and the recently identified MULT1 (Cerwenka et al., (2000) Immunity 12, 721-727; Diefenbach et al., (2000) Nat. Immunol. 1, 119-126; Carayannopoulos et al. (2002), J. Immunol 169, 4079-4083). Human ligands include
15 the MHC class I chain-related genes MICA and MICB (Bauer et al. (1999) Science 285, 727-729) and the UL16-binding protein ULBP family (Cosman et al. (2001) Immunity 14, 123-133).

20 MIC proteins have three α domains structurally similar to those of classical MHC class I molecules, but they do not bind peptides or associate with β 2 microglobulin. H60, ULBP1-3 and the Rae-1 family only possess MHC-like α 1 α 2 domains. The human ULBP and murine Rae-1 proteins are
25 distinct from the other NKG2D ligands, as they are GPI anchored to the membrane, rather than possessing a transmembrane (TM) region.

NKG2D exists as a homodimer at the cell surface. Diverse
30 ligands bind to only five conserved 'hotspots' within the NKG2D binding site (McFarland et al. Immunity (2003) 19, 803-812; McFarland et al Structure (2003) 11, 411-422). NKG2D is not limited to NK cells and is also expressed on

activated CD8⁺ T cells, $\gamma\delta$ T cells, and activated macrophages (Jamieson et al. (2002) *Immunity* 17, 19-29).

The expression of NKG2D ligands is poorly understood.

5 MIC is frequently expressed on tumours of epithelial origin (Groh et al. (1999) *Proc. Natl. Acad. Sci. USA* 96, 6879-6884) and upregulation of NKG2D ligands on tumours may be a mechanism for immune recognition and elimination of malignant cells. A study of tumor susceptibility to
 10 NKG2D-dependent natural killer cell cytotoxicity indicates that the involvement of NKG2D in natural killer cell-mediated cytotoxicity strictly correlates with the expression and the surface density of MICA and ULBP on target cell tumors of different histotypes (Pende et al.
 15 (2002) *Cancer Res.*, 62, 6178-6186). In mouse models, implanted tumour cells transfected with NKG2D ligands invoked potent antitumour immunity and rejection of tumour cells *in vivo* (Diefenbach et al. (2000) *Nat. Immunol.* 1, 119-126; Cerwenka et al. (2001) *Proc. Natl. Acad. Sci. USA* 98, 11521-11526; Diefenbach et al. (2001)
 20 *Nature* 413, 165-171; Girardi et al. (2001) *Science* 294, 605-609). NKG2D ligands may also have a role in the immune response to pathogens, including cytomegalovirus (Groh et al. (2001) *Immunol.* 2, 255-260) *Mycobacterium tuberculosis* (Das et al. (2001) *Immunity* 15, 83-93) and
 25 *Escherichia coli* (Tieng et al. (2002) *Proc. Natl. Acad. Sci.* 99, 2977-2982).

NK cell function is impaired in non-obese diabetic (NOD)
 30 mice by expression of NKG2D ligands on the NK cells (Ogasawara et al., (2003) *Immunity* 18, 41-51). In rheumatoid arthritis, interaction of the NKG2D receptor with its ligands is impaired (Groh et al., (2003) *Proc. Natl. Acad. Sci. USA* 100, 9452-9457).

Expression of Unique Long (UL) 16 glycoprotein by human cytomegalovirus (hCMV) may be a mechanism by which hCMV evades immune recognition by interfering with NKG2D binding to its ligands (Cosman et al. (2001) *Immunity* 14, 123-133; Welte et al. (2003) *Eur. J. Immunol.* 33, 194-203). Not all human MIC and ULBP proteins are targeted. MICB, ULBP1, and ULBP2 are bound by UL16 whereas MICA and ULBP3 are not. Similarly, different murine ligands have variable affinities for NKG2D (Carayannopoulos et al. (2002) *J. Immunol.* 169, 4079-4083; O'Callaghan et al. (2001) *Immunity* 15, 201-211; Carayannopoulos et al (2002) *Eur. J. Immunol.* 32, 597-605). MIC and ULBP proteins can be expressed independently of each other on cells of different lineages, which is also consistent with non-redundant functions (Pende et al. (2002) *Cancer Res.* 62, 6178-6186)

A number of ULBP-related genes (the 'RAE1-like transcripts' (RAET1)) have been identified in a cluster on chromosome 6p24.2-q25.3 (Radosavljevic et al. (2002) *Genomics* 79, 114-123). This cluster includes several new genes distinct from ULBP1-3, including RAET1E (US2003/0195337).

The present invention relates to the identification and characterisation of a novel member of the RAET1/ULBP family of proteins, termed 'RAET1G'. RAET1G is shown herein to bind the UL16 and NKG2D receptors with an affinity significantly higher than any of the ULBP family of proteins reported to date.

One aspect of the present invention provides an isolated nucleic acid encoding a polypeptide which comprises or

consists of an amino acid sequence having at least 87% sequence identity or at least 87% sequence similarity with the amino acid sequence of figure 1 or figure 2.

- 5 The polypeptide may comprise or consist of an amino acid sequence of at least 90% sequence identity or similarity, at least 95% sequence identity or similarity, or at least 98% sequence identity or similarity with the amino acid sequence of figure 1. In some preferred embodiments, the
10 polypeptide may comprise or consist of the amino acid sequence of Figure 1 and/or figure 2.

Preferably, the polypeptide has one or more RAET1G functions. For example, the polypeptide may bind to UL16
15 (Acc No. AY297445) and/or NKG2D (Acc No. AF481811), preferably with high affinity (i.e. 360nM or less)

An isolated nucleic acid as described herein may share greater than about 85% sequence identity with the nucleic acid sequence of figure 3 or figure 4, greater than about
20 90%, or greater than about 95%.

The nucleic acid may comprise or consist of a sequence shown in Figure 3 or figure 4, it may be a mutant, variant, derivative or allele of the sequence shown. The
25 sequence may differ from that shown by a change that is one or more of addition, insertion, deletion and substitution of one or more nucleotides of the sequence shown. Changes to a nucleic acid sequence may result in
30 an amino acid change at the protein level, or not, as determined by the genetic code.

Thus, a nucleic acid may include a sequence different from the sequence shown in figure 3 or figure 4, yet encode a polypeptide with the same amino acid sequence.

5 Sequence identity is described in more detail below.

A nucleic acid of the invention may hybridise with the sequence shown in figure 3 and/or figure 4 under stringent conditions, or may have a complement which
10 hybridises to the sequence shown in figure 3 and/or figure 4 under stringent conditions. Suitable conditions include, e.g. for sequences that are about 80-90% identical, suitable conditions include hybridisation overnight at 42°C in 0.25M Na₂HPO₄, pH 7.2, 6.5% SDS, 10%
15 dextran sulphate and a final wash at 55°C in 0.1 X SSC, 0.1% SDS. For sequences that are greater than about 90% identical, suitable conditions include hybridisation overnight at 65°C in 0.25M Na₂HPO₄, pH 7.2, 6.5% SDS, 10%
20 dextran sulphate and a final wash at 60°C in 0.1X SSC, 0.1% SDS. Preferably, a nucleic acid encodes a polypeptide with RAET1G activity, as described above.

The invention also includes fragments of nucleic acid sequences as described herein, for example, a fragment of
25 the nucleotide sequence of Figure 3 or figure 4. Suitable fragments may consist of less than 891 nucleotides, for example from 10, 20, 30, 40 or 50 nucleotides to 800, 870, 880 or 891 nucleotides. Such a fragment may encode a RAET1G polypeptide as described below, or may be useful
30 as an oligonucleotide probe or primer.

Another aspect of the present invention provides an isolated RAET1G polypeptide encoded by a nucleic acid

sequence described above, for example the nucleic acid sequence of figure 3 or 4.

5 A polypeptide may comprise or consist of the amino acid sequence shown in figure 1 and/or figure 2 or may be a variant, allele, derivative or mutant thereof.

10 A variant, allele, derivative or mutant of an RAET1G polypeptide as described herein may include a polypeptide modified by varying the amino acid sequence of the protein, e.g. by manipulation of the nucleic acid encoding the protein or by altering the protein itself. Such derivatives of the natural amino acid sequence may involve one or more of insertion, addition, deletion or
15 substitution of one or more amino acids, which may be without fundamentally altering the qualitative activity of the polypeptide, for example the binding of the polypeptide to the UL16 receptor and/or the NKG2D receptor.

20

A variant, allele, derivative or mutant may comprise an amino acid sequence which shares greater than about 87% sequence identity with the sequence of figure 1, greater than about 90% or greater than about 95%. The sequence
25 may share greater than about 87% similarity with the amino acid sequence of figure 1 and/or figure 2, or greater than about 90% similarity. Preferably, an amino acid sequence variant, allele, derivative or mutant of an RAET1G polypeptide retains binding affinity for the UL16
30 receptor and/or the NKG2D receptor.

Sequence similarity and identity are commonly defined with reference to the algorithm GAP (Genetics Computer Group, Madison, WI). GAP uses the Needleman and Wunsch

algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4.

5

Use of GAP may be preferred but other algorithms may be used, e.g. BLAST (which uses the method of Altschul et al. (1990) J. Mol. Biol. 215, 405-410), FASTA (which uses the method of Pearson and Lipman (1988) Proc. Natl. Acad. USA 85, 2444-2448), or the Smith-Waterman algorithm (Smith and Waterman (1981) J. Mol Biol. 147, 195-197), or the TBLASTN program, of Altschul et al. (1990) supra, generally employing default parameters. In particular, the psi-Blast algorithm (Nucl. Acids Res. (1997) 25, 3389-3402) may be used. Sequence identity and similarity may also be determined using GenomequestTM software (Gene-IT, Worcester MA USA).

Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. Particular amino acid sequence variants may differ from a known polypeptide sequence as described herein by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5-10, 10-20 20-30, 30-50, or more than 50 amino acids.

Sequence comparison is made over the full-length of the relevant sequence described herein, except when context dictates otherwise.

An RAET1G polypeptide may include a polypeptide fragment which consists of fewer amino acid residues than the full-length polypeptide, for example the full length sequence of figure 1 and/or figure 2. Such a fragment may consist of at least 110 amino acids, more preferably at least 160 amino acids, more preferably at least 200 amino acids, more preferably at least 250 amino acids, more preferably at least 297 amino acids. Such a fragment may consist of 297 amino acids or less, 250 amino acids or less, or 160 amino acids or less, or 110 amino acids or less.

Preferably, a polypeptide as described herein comprises $\alpha 1$ and $\alpha 2$ domains corresponding to at least residues 83 to 202 in the sequence of figure 1 or figure 2.

The polypeptide may also comprise a transmembrane domain corresponding to at least residues 227-242 in the sequence of figure 1 or figure 2, and/or a cytoplasmic domain corresponding to at least residues 243-297 or fewer in the sequence of figure 1 or figure 2.

A polypeptide as described herein may further comprise a proline residue at a position corresponding to position 163 of the amino acid sequence of figure 1 or figure 2.

Amino acid residues are described in the present application with reference to their position in the sequence of figure 1. It will be appreciated that the equivalent residues in other RAET1G polypeptides may have a different position and number, because of differences in the amino acid sequence of each polypeptide. These differences may occur, for example, through variations in the length of the N terminal domain. Equivalent residues

in RAET1G polypeptides are easily recognisable by their overall sequence context and by their positions with respect to the $\alpha 1$ and $\alpha 2$ domains.

- 5 A polypeptide as described herein may be soluble or insoluble, for example a polypeptide may be anchored to or within a membrane.

10 Preferably, a polypeptide has RAET1G function and binds with high affinity to a UL16 receptor and/or a NKG2D receptor. The affinity of an RAET1G polypeptide for a UL16 and/or an NKG2D receptor may be determined by any one of a range of standard techniques, including for example, surface plasmon resonance.

15 High affinity binding to a receptor is, in general, binding of sub-micromolar affinity. Moderate-low affinity binding is, in general, binding of micromolar or tens of micromolar affinity.

20 RAET1G polypeptides as described herein bind with a comparable or, more preferably, a higher affinity than the binding affinity of other NKG2D ligands, such as ULBP1 with an affinity for NKG2D of 1.68 μ M.

25 An RAET1G polypeptide may also comprise additional amino acid residues which are heterologous to the RAET1G sequence. For example, an RAET1G polypeptide as described above may be included as part of a fusion
30 protein, where the heterologous amino acid residues enable the fusion protein to have a function in addition to binding affinity for the UL16 and/or NKG2D receptors. For example, the additional function may provide a

desired property, or may allow an agent with a desired property to be joined to the fusion protein.

In some embodiments, a RAET1G polypeptide may be
5 chemically attached to a functional moiety in a
conjugate. Functional moieties which may be conjugated
with a RAET1G polypeptide include polypeptides, non-
peptidyl chemical compounds, cells and virus particles.
A functional moiety may, for example, have cytotoxic
10 activity or a binding activity.

The skilled person can use the techniques described
herein and others well known in the art to produce large
amounts of polypeptides and peptides, for instance by
15 expression from encoding nucleic acid.

A method of producing an RAET1G polypeptide may comprise;
(a) causing expression from a nucleic acid which encodes
a RAET1G polypeptide to produce the RAET1G polypeptide
20 recombinantly; and,
(b) testing the recombinantly produced polypeptide for
RAET1G activity.

Suitable nucleic acid sequences include a nucleic acid
25 sequence encoding an RAET1G polypeptide as described
above.

A polypeptide may be isolated and/or purified (e.g. using
an antibody for instance) after production by expression
30 from encoding nucleic acid (for which see below). Thus,
a polypeptide may be provided free or substantially free
from contaminants with which it is naturally associated
(if it is a naturally-occurring polypeptide). A

polypeptide may be provided free or substantially free of other polypeptides.

5 Fusion polypeptides may be generated to facilitate purification of the RAET1G polypeptide. For example, six histidine residues may be incorporated at either the N-terminus or C-terminus of the recombinant protein. Such a histidine tag may be used for purification of the protein by using commercially available columns which
10 contain a metal ion, either nickel or cobalt (Clontech, Palo Alto, CA, USA).

The recombinantly produced polypeptide may be isolated and/or tested for RAET1G activity by determination of the
15 binding affinity for the UL16 receptor and/or the NKG2D receptor by incubation of the RAET1G polypeptide with the receptor and quantification of binding affinity using surface plasmon resonance.

20 An isolated nucleic acid as described above, for example a nucleic acid encoding an RAET1G polypeptide, may be comprised in a vector. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments,
25 polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989,
30 Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins,

are described in detail in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. A common, preferred bacterial host is *E. coli*.

Further aspects of the present invention provide a host cell containing heterologous nucleic acid encoding an RAET1G polypeptide as described above.

Host cells, in particular host cells which are cancer cells, may be useful in the treatment of a cancer condition, for example by stimulating an immune response to the cancer cells in the host organism.

The nucleic acid may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell.

The introduction of nucleic acid into a host cell, which may (particularly for in vitro introduction) be generally referred to without limitation as "transformation", may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate

transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques
5 may include calcium chloride transformation, electroporation and transfection using bacteriophage.

Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing
10 nucleic acid of interest, as is well known in the art.

The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed
15 although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded polypeptide is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell
20 into the culture medium.

Following production by expression, a polypeptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, tested for RAET1G
25 activity and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see
30 below).

In other embodiments, the host cell comprising the expressed polypeptide, for example at the cell surface, may be isolated and/or purified and formulated in a

pharmaceutical composition, for example for the treatment of a cancer or other RAET1G mediated condition.

Another aspect of the present invention provides an
5 isolated antibody that binds specifically to a RAET1G polypeptide.

Antibodies may be obtained using techniques that are standard in the art. Methods of producing antibodies
10 include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding
15 of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al., (1992) Nature 357, 80-82). Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of
20 sacrificing the animal.

As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of
25 expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. The library may be naive, that is constructed from sequences obtained
30 from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed, the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimicks that of an antibody enabling it to bind an antigen or epitope.

10

Antibodies which specifically bind to a RAET1G polypeptide may, for example, be useful in determining whether an individual has cancer.

15 Cancer cells are shown herein to differentially splice RAET1G transcripts to produce a truncated RAET1G polypeptide which lacks the RAET1G transmembrane and cytoplasmic domains (i.e. a soluble RAET1G polypeptide).

20 A method of identifying a cancer condition in an individual may comprise; determining the expression of a soluble RAET1G polypeptide in a sample obtained from the individual.

25 Expression of a soluble RAET1G polypeptide may be determined by determining the presence or amount of soluble RAET1G polypeptide in the sample.

The presence or amount of soluble RAET1G polypeptide may be determined directly by contacting the sample with an antibody as described herein.

30

The presence of RAET1G polypeptide in a sample taken from an individual is indicative that the individual has a

cancer condition, for example a leukaemia condition such as T-cell leukaemia.

5 A soluble RAET1G polypeptide may comprise or consist of the amino acids 1-213 of the full length RAET1G sequence.

10 The sample may be a tissue biopsy sample, for example from tissue suspected of disease or malignancy, or may be a biological fluid sample, for example from blood, serum or plasma. A biological sample may comprise cells which may, optionally, be concentrated and/or isolated prior to contacting with the antibody.

15 The reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be direct or indirect, 20 covalent, e.g. via a peptide bond, or non-covalent. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion that encodes antibody and reporter molecule. The mode of determining binding is not a feature of the present invention and 25 those skilled in the art are able to choose a suitable mode according to their preference and general knowledge. For example, a range of conventional techniques are available to determine and/or quantify the binding of antibody to RAET1G polypeptide, including for example, 30 HPLC or ELISA.

An antibody as described herein may be a component of a kit for detecting a cancer condition in an individual, using a method as described herein.

In other embodiments, the expression of a soluble RAET1G polypeptide may be determined indirectly by determining the level of nucleic acid encoding soluble RAET1G in the sample.

A method of identifying a cancer condition in an individual may comprise; determining the presence or amount of nucleic acid encoding a soluble RAET1G polypeptide in a sample obtained from the individual.

Nucleic acid encoding a soluble RAET1G polypeptide may include a nucleic acid which encodes the amino acid sequence of figure 1 of the RAET1G sequence. A suitable nucleic acid may, for example, comprise or consist of the sequence of figure 3, or be an allele or variant thereof.

The presence or amount of a nucleic acid, in particular an RNA, may be determined by any convenient techniques, including, for example RT-PCR or Northern Blotting.

The invention also encompasses the use of an RAET1G polypeptide as described herein in a method for obtaining or identifying a modulator, for example an inhibitor, of RAET1G and/or its interaction with UL16 and/or NKG2D receptors.

A method for obtaining and/or identifying a modulator of a RAET1G polypeptide may comprise;

- (a) bringing into contact a RAET1G polypeptide and a test compound; and,
- (b) determining the interaction of the RAET1G polypeptide with the test compound.

In other embodiments, a method for obtaining and/or identifying a modulator of a RAET1G polypeptide may comprise;

- 5 (a) bringing into contact a RAET1G polypeptide and a UL16 or NKG2D polypeptide in the presence of a test compound; and,
- (b) determining the interaction between the UL16 or NKG2D polypeptide and the RAET1G polypeptide.

10

Interaction or binding may be determined in the presence and absence of test compound. A difference in interaction or binding in the presence of the test compound relative to the absence of test compound may be
15 indicative of the test compound being a modulator of RAET1G activity.

Polypeptides may be contacted under conditions wherein, in the absence of the test compound, the polypeptides
20 interact or bind to each other. The RAET1G polypeptide may be in the reaction medium in an isolated form or may be comprised on a cell membrane.

Methods for obtaining or identifying RAET1G modulators as
25 described herein may be *in vivo* cell-based assays, or *in vitro* non-cell-based assays. In *in vitro* assays, the RAET1G polypeptide may be isolated, fixed to a solid support or comprised on a membrane. Suitable cell types for *in vivo* assays include mammalian cells such as CHO,
30 HeLa and COS cells.

The precise format of the methods described herein may be varied by those of skill in the art using routine skill and knowledge.

It is not necessary to use the entire full-length RAET1G, UL16 or NKG2D polypeptides for *in vitro* or *in vivo* assays of the invention. Polypeptide fragments as
5 described herein which retain the activity of the full length protein may be generated and used in any suitable way known to those of skill in the art.

For example, binding affinity may be studied *in vitro* by
10 immobilising either the RAET1G polypeptide or one or both of the UL16 and NKG2D receptor to a solid support, then bringing it into contact with the other. The binding affinity can then be determined by standard techniques, such as surface plasmon resonance. The RAET1G polypeptide
15 or the receptor may be labelled with a detectable label. Suitable detectable labels include ^{35}S -methionine which may be incorporated into recombinantly produced peptides and polypeptides. Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein
20 containing an epitope which can be labelled with an antibody.

A method described herein may be performed *in vivo*, for example in a cell line such as a yeast or mammalian cell
25 line in which the relevant polypeptides or peptides are expressed from one or more vectors introduced into the cell.

The ability of a test compound to modulate interaction
30 between a RAET1G polypeptide and a UL16 or NKG2D polypeptide may be determined using a so-called two-hybrid assay. For example, a polypeptide or peptide containing a fragment of a RAET1G polypeptide or UL16 or NKG2D polypeptide as the case may be, or a peptidyl

analogue or variant thereof as disclosed, may be fused to a nucleic acid binding domain such as that of the yeast transcription factor GAL 4. The GAL 4 transcription factor includes two functional domains. These domains are the DNA binding domain (GAL4DBD) and the GAL4 transcriptional activation domain (GAL4TAD). By fusing one polypeptide or peptide to one of those domains and another polypeptide or peptide to the respective counterpart, a functional GAL 4 transcription factor is restored only when two polypeptides or peptides of interest interact. Thus, interaction of the polypeptides or peptides may be measured by the use of a reporter gene probably linked to a GAL 4 DNA binding site that is capable of activating transcription of said reporter gene. This assay format is described by Fields and Song, 1989, Nature 340; 245-246. This type of assay format can be used in both mammalian cells and in yeast.

Other combinations of nucleic acid binding domain and transcriptional activation domain are available in the art and may be preferred, such as the LexA DNA binding domain and the VP60 transcriptional activation domain. In some embodiments, the RAET1G, UL16 or NKG2D polypeptide or peptide may be employed as a fusion with (e.g.) the LexA DNA binding domain, and the counterpart (e.g.) UL16, NKG2D or RAET1G, polypeptide or peptide as a fusion with (e.g.) VP60, and involves a third expression cassette, which may be on a separate expression vector, from which a peptide or a library of peptides of diverse and/or random sequence may be expressed. A reduction in reporter gene expression (e.g. in the case of β -galactosidase a weakening of the blue colour) results from the presence of a peptide which disrupts the RAET1G/receptor (for example) interaction, which

interaction is required for transcriptional activation of the β -galactosidase gene. Where a test substance is not peptidyl and may not be expressed from encoding nucleic acid within a said third expression cassette, a similar
5 system may be employed with the test substance supplied exogenously.

When performing a two hybrid assay to look for substances which interfere with the interaction between two
10 polypeptides or peptides it may be preferred to use mammalian cells instead of yeast cells. The same principles apply and appropriate methods are well known to those skilled in the art.

15 The RAET1G, UL16 and/or NKG2D polypeptides may be present on and/or in a cell or different cells. This may be achieved, for example by expressing the polypeptides from one or more expression vectors which have been introduced into the cell by transformation.

20

A suitable UL16 polypeptide may include Human Cytomegalovirus (HCMV) UL16 (Acc No. AY297445) or a variant, homologue, mutant, allele or derivative thereof.

A variant, allele, derivative, homologue, or mutant of
25 UL16 may consist of a sequence having greater than about 70% sequence identity with the sequence of HCMV UL16, greater than about 80%, greater than about 90%, or greater than about 95%.

30 A suitable NKG2D receptor may include the human NKG2D receptor (Acc No. AF481811) or a variant, homologue, mutant, allele or derivative thereof. A variant, allele, derivative, homologue, or mutant of NKG2D may consist of a sequence having greater than about 70% sequence

identity with the sequence of human NK cell NKG2D receptor, greater than about 80%, greater than about 90%, or greater than about 95%.

5 The amount of test substance or compound which may be added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.001 nM to 1mM or more concentrations of putative inhibitor compound may be
10 used, for example from 0.01 nM to 100µM, e.g. 0.1 to 50 µM, such as about 10 µM. When cell-based assays are employed, the test substance or compound is desirably membrane permeable in order to access the RAET1G polypeptide.

15 Test compounds may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used.

20 Combinatorial library technology (Schultz, (1996) Biotechnol. Prog. 12, 729-743) provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a
25 polypeptide.

One class of test compounds can be derived from the RAET1G, UL16 and/or NKG2D polypeptides. Membrane permeable peptide fragments of from 5 to 40 amino acids,
30 for example, from 6 to 10 amino acids may be tested for their ability to modulate such interaction or activity.

Peptides can also be generated wholly or partly by chemical synthesis according to well-established,

standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, 5 Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California). Peptides may be prepared in solution, by the 10 liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by 15 reaction of the respective carbonic or sulphonic acid or a reactive derivative thereof. The modulatory properties of a peptide may be enhanced by the addition of one of the following groups to the C terminal: chloromethyl ketone, aldehyde and boronic acid. These groups are 20 transition state analogues for serine, cysteine and threonine proteases. The N terminus of a peptide fragment may be blocked with carbobenzyl to inhibit aminopeptidases and improve stability (Proteolytic Enzymes 2nd Ed, Edited by R. Beynon and J. Bond Oxford 25 University Press 2001).

Other candidate modulator compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment and using rational drug design to 30 provide potential inhibitor compounds with particular molecular shape, size and charge characteristics. This is described in more detail below.

Antibodies directed to RAET1G polypeptide may form a further class of putative modulator compounds. Candidate antibodies may be characterised and their binding regions determined to provide single chain antibodies and
5 fragments thereof which are responsible for modulating the interaction.

Following identification of a compound using a method described above, the compound may be isolated and/or
10 synthesised.

An agent identified using one or more primary screens (e.g. in a cell-free system) as having ability to interact with RAET1G and/or a receptor, such as UL16 or
15 NKG2D, and/or modulate activity of RAET1G may be assessed or investigated further using one or more secondary screens. Biological activity, for example, may be tested in an NK cell cytotoxicity assay. Test compounds found to modulate the activity of RAET1G may be tested for
20 activity in inhibiting NK cell cytotoxicity.

Following identification of a compound as described above, a method may further comprise modifying the compound to optimise the pharmaceutical properties
25 thereof.

The modification of a 'lead' compound identified as biologically active is a known approach to the development of pharmaceuticals and may be desirable where
30 the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides are not well suited as active agents for oral compositions as they tend to be quickly degraded by proteases in the

alimentary canal. Modification of a known active compound (for example, to produce a mimetic) may be used to avoid randomly screening large number of molecules for a target property.

5

Modification of a 'lead' compound to optimise its pharmaceutical properties commonly comprises several steps. Firstly, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn. These parts or residues constituting the active region of the compound are known as its "pharmacophore".

Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, X-ray diffraction data and NMR.

Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process.

In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the optimisation of the lead compound.

35

A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to it can conveniently be selected so that the modified
5 compound is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound. The modified compounds found by this approach can then be screened to see whether they have the target
10 property, or to what extent they exhibit it. Modified compounds include mimetics of the lead compound.

Further optimisation or modification can then be carried out to arrive at one or more final compounds for in vivo
15 or clinical testing.

The test compound may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical
20 composition or drug. These may be administered to individuals, e.g. for any of the purposes discussed elsewhere herein.

A method of the invention may comprise formulating said
25 test compound in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier as discussed further below.

Another aspect of the present invention provides a method
30 of producing a pharmaceutical composition comprising;
i) identifying a compound which modulates the activity of an RAET1G polypeptide using a method described herein;
and,

ii) admixing the compound identified thereby with a pharmaceutically acceptable carrier.

The formulation of compositions with pharmaceutically acceptable carriers is described further below.

Another aspect of the invention provides a method for preparing a pharmaceutical composition, for example, for the treatment of a condition which is mediated by RAET1G, comprising;

- i) identifying a compound which is an agonist or antagonist of a RAET1G polypeptide
- ii) synthesising the identified compound, and;
- iii) incorporating the compound into a pharmaceutical composition.

The identified compound may be synthesised using conventional chemical synthesis methodologies. Methods for the development and optimisation of synthetic routes are well known to persons skilled in this field.

The compound may be modified and/or optimised as described above.

Incorporating the compound into a pharmaceutical composition may include admixing the synthesised compound with a pharmaceutically acceptable carrier or excipient.

Another aspect of the present invention provides a modulator, for example an inhibitor, of RAET1G activity, or composition comprising such a modulator, which is isolated and/or obtained by a method described herein.

Suitable modulators may include small chemical entities, peptide fragments, antibodies or mimetics as described above.

5 Another aspect of the invention provides a pharmaceutical composition comprising a modulator as described herein and a pharmaceutically acceptable excipient, vehicle or carrier.

10 Another aspect of the invention provides an RAET1G polypeptide or fragment thereof, or a nucleic acid encoding a RAET1G polypeptide or fragment thereof, or an antibody, cell or a modulator, as described above, for use in the treatment of a human or animal body.

15 Another aspect of the invention provides the use of a RAET1G polypeptide or fragment thereof, nucleic acid encoding a RAET1G polypeptide or fragment thereof, antibody as described herein, host cell as described
20 herein, or a modulator obtained by a method described herein, in the manufacture of a composition for the treatment of an individual with a disorder mediated by RAET1G.

25 A disorder mediated by RAET1G may include a pathogenic infection, a cancer condition or an immune disorder.

A pathogenic infection may include a bacterial infection, such as an *Mycobacterium tuberculosis* or *Escherichia coli*
30 infection or a viral infection, such as a human cytomegalovirus infection.

A cancer condition may include lung cancer, gastrointestinal cancer, bowel cancer, colon cancer,

breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma, lymphoma or
5 leukaemia.

A condition of the immune system may include autoimmune diseases, such as rheumatoid arthritis, lupus, scleroderma, Sjögren's syndrome and multiple sclerosis,
10 diabetes or inflammatory bowel diseases such as inflammatory bowel syndrome, ulcerative colitis and Crohn's disease. It may also be useful for patients who have undergone transplant surgery, to reduce or prevent rejection.

15 Whether it is a cell, polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual,
20 administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount
25 administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors.

30 A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, or Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Aspects of the present invention will now be illustrated with reference to the accompanying figures described below and experimental exemplification, by way of example and not limitation. Further aspects and embodiments will be apparent to those of ordinary skill in the art. All documents mentioned in this specification are hereby incorporated herein by reference.

Figure 1 amino acid sequence of the RAET1G2 polypeptide.

Figure 2 shows the amino acid sequence of the RAET1G polypeptide

Figure 3 shows the nucleic acid sequence encoding the full-length amino acid sequence of the RAET1G polypeptide (coding sequence (CDS) nucleotides 69 to 1072).

Figure 4 shows the nucleic acid sequence encoding the alternatively spliced RAET1G polypeptide, consisting of aminoacid residue 1-214 of the sequence shown in figure 1 (coding sequence is nt 1-642).

Figure 5 shows the arrangement of expressed genes in the RAET1 cluster on chromosome 6q24.2-q25.3.

Figure 6 shows a phylogenetic tree of murine and human NKG2D ligands. Murine ligands are identified by an 'm' prefix.

Figure 7 shows a sequence alignment of RAET1G, ULBP2, RAET1E, and ULBP3. Putative TM regions are in bold letters and signal peptide sequences are underlined. Symbols indicate proposed α -helical (black cylinders), 3_{10} helical (grey cylinder) and β -strand (grey arrow).

Figure 8 shows exon structures of RAET1G and RAET1G2.

Figure 9 shows the expression of RAET1E and RAET1G in
 5 cell lines, screened using RT-PCR. Specific primers were
 used, such that RAET1G2 gave a product of 835bp and
 RAET1G a product of 935bp, respectively. The RAET1E
 product is 810bp. Upper panel is RAET1G, second panel
 RAET1E. GAPDH on the lower panel was used as a positive
 10 loading control. The cell lines used were: 1-Daudi (B
 cell), 2-721.221 (B cell), 3-HSB-2 (T cell), 4-Jurkat (T
 cell), 5-THP-1 (monocyte), 6-HeLa (cervical carcinoma),
 7-HT1080 (fibrosarcoma), 8- MelJuSo (melanoma), 9- K562
 (eyrthroid), 10- NKL (NK cell like), 11-Raji (B cell),
 15 12-RPMI-8402 (T cell), 13 HPB-ALL (T cell), 14-MOLT-4 (T
 cell), 15-MOLT-13 (T cell), 16-CCRF-CEM (T cell), 17-Fern
 (B cell), 18-Ind (B cell), 19-U937 (pre-monocyte), 20-YT
 (NK cell like), 21- HUVEC (umbilical vein), 22-HepG2
 (liver carcinoma). Track 23 (right) contains RAET1G cDNA
 20 control in the upper panel and RAET1E control in the
 second.

Figure 10 shows expression of the RAET1G2 form in the T
 cell leukaemia line HSB-2. PCR products from left to
 25 right: RAET1G standard, RAET1G2 standard, K562, and HSB-2
 cell lines.

Figure 11 shows the expression of RAET1G in 5 different
 normal tissues. RAET1G expression is in the upper panel,
 30 GAPDH on the lower panel was used as a positive loading
 control. Tissue cDNA tested 1) Bone Marrow, 2) Colon, 3)
 Peripheral Blood Lymphocytes, 4) Placenta, 5) Tonsil 6)
 positive control cDNA

Figure 12 shows cell surface expression of RAET1 proteins in COS-7 cells. From left to right:- mock transfected cells, ULBP2, RAET1G and RAET1E transfected cells. Upper panel stained with FITC-isotype control, Lower panel with anti-flag antibody.

Figure 13 shows a histogram denoting transfected cells stained with anti flag antibody - cells only (solid black line), ULBP2 (solid grey line), RAET1G (dashed grey line) and RAET1E (dashed black line).

Figure 14 shows binding of NKG2D-Fc cells to surface-expressed RAET1 in COS-7 cells. From left to right mock transfected cells, ULBP2, RAET1G and RAET1E transfected cells. Upper panel stained with FITC-isotype control, Lower panel with NKG2D-Fc - anti human Fc-FITC.

Figure 15 shows a histogram denoting transfected cells stained with NKG2D - cells only (solid black line), ULBP2 (solid grey line), RAET1G (dashed grey line) and RAET1E (dashed black line).

Figure 16 shows the % specific lysis of COS-7 cells transfected with novel RAET1 molecules at different effector:target ratios. The transfected cells were incubated with either CD3⁻ CD56⁺ NKG2D⁺ human natural killer lymphocytes (black squares), or CD3⁻ CD56⁺ NKG2D⁺ human natural killer lymphocytes and NKG2D-specific monoclonal antibody (open circles). RAET1E, top panel; RAET1G, middle panel; vector only, bottom panel.

Figure 17 shows BIACore plots used in kinetic analysis. Panels 1 and 2 show RAET1G and RAET1E binding to NKG2D-Fc

respectively, at dilutions as shown. Panels 3 and 4, show RAET1G and RAET1E binding to UL16-Fc.

Table 1 shows the kinetic binding data for human
5 RAET1/ULBP proteins binding to NKG2D and UL16.

Table 2 shows a compilation of published data for murine and human NKG2D ligands.

10 EXPERIMENTAL

Materials and Methods

Molecular cloning of the ULBP family

The 5' end of RAET1G was predicted by alignment of the EST sequences AW510737, BE711112, BF513861 and the
15 genomic DNA (contig NT_023451.10). The predicted sequence matched with two IMAGE clone 3070730 and 2911855. IMAGE clone 3070730 had a truncated 3' end and missed the stop codon. The correct 3' end was predicted from EST AA583860 and confirmed by PCR. The signal peptide was predicted
20 with Signal PV1.1 and the predicted transmembrane region was detected with TMPred (K. Hofmann & W. Stoffel (1993) Biol. Chem. Hoppe-Seyler 374,166). The exon structures were analysed with the GCG program (Wisconsin package) version 10.3.

25

The alignment was based on the global amino acid sequences or on local domains of RAET1L (NM_130900.1), RAET1E (AY176317), RAET1G (AY172579), ULBP1 (NM_0225218.1), ULBP2 (NM_025217.2), ULBP3 (NM_024518.1),
30 MICA (BC016929), MICB (NM_005922.1) and MULT1 (AK020784) and conducted using ClustalW (Higgins D et al. (1994) Nucleic Acids Res. 22:4673-4680) and PileUp. The UPGMA (unweighted pair group method with arithmetic mean) tree was constructed by the program MEGA version 2.1 (Kumar,

S. et al (2001). *Bioinformatics*, 17, 1244-5). The consistency of the branches was assessed by bootstrap based on 1000 sample per runs.

- 5 The following clones were obtained from the I.M.A.G.E clone collection, HGMP, Hinxton, Cambs, UK: RAET1G: IMAGE No. 3070730, 2911855, RAET1E: 3464637, ULBP2: 4747126 (Genbank accessions BF513861, AW 510737, BE545401, BG675590).

10

DNA sequencing was performed using BigDye and ABI 377 sequencer, analysis using Sequence Navigator software. Full-length receptor constructs were cloned as Flag epitope fusions in vector p3XFLAG-CMVTM-9 (Sigma). Topo cloning of PCR fragments was performed using the Topo cloning kit (Invitrogen) and the manufacturer's instructions.

- 20 RT-PCR
PCR primers used for determining tissue distribution:
- | | | |
|----|-----------|--------------------------|
| 1G | For | 5' AGCCCCGCGTTCCTTCTA |
| | Rev | 5' TGTATACAAGGCAAGAGGGGC |
| 1E | For | 5' TATCCCTGACTTCTAGCCCT |
| | Rev | 5' GCCACTCACCATTTTGCCAC |
| 25 | GAPDH For | 5' ACCACAGTCCATGCCATCAC |
| | Rev | 5' TCCACCACCCTGTTGCTGTA |

Cell line RNA's were made as previously described (Allcock et al., (2003) *Eur. J. Immunol.* 33, 567-577).

- 30 Expected sizes of products were: 935bp for RAET1G, 835bp for RAET1G2 and 810bp for RAET1E. GAPDH was used as a control reaction for each cDNA.

Transfections and Flow Cytometry

Transient transfections were performed into CV-1 cells using Lipofectamine 2000 (Invitrogen) and the manufacturer's standard protocol. Flow cytometry was performed on a Becton FACScalibur machine. Detection of the full-length receptors was via a FITC-conjugated monoclonal antibody to the FLAG[®] epitope (Sigma). Detection of NKG2D binding was via the human Fc fusion, using an anti-human IgG FITC conjugated polyclonal antibody (Dako).

10

NK cell cytotoxicity assay

Human natural killer (NK) lymphocytes were isolated from peripheral blood using standard Ficoll isolation of mononuclear cells followed by staining with anti-CD3-FITC and anti-CD56-CyChrome (Becton Dickinson UK) monoclonal antibodies. Stained cells were analysed on a MoFlo cell sorter (Cytomation) and the CD3⁻ CD56⁺ lymphocyte population isolated. These cells were incubated in RPMI 1640 medium containing penicillin and streptomycin, 10% human AB serum and 100U/ml recombinant interleukin-2 for three days at 37°C, 5% CO₂. Flow cytometric analysis demonstrated that this polyclonal population of NK cells were uniformly CD3⁻ CD56⁺ NKG2D⁺.

25 The ability of novel human RAET1 molecules to induce natural killer cell mediated lysis was assessed by an in vitro non-radioactive cytotoxicity assay (Sheehy et al., (2001) J. Immunological Methods 249, 99-110). Four wells of labelled target cells alone were set up to determine spontaneous release and each labelled target cell was assessed in duplicate at a range of effector to target ratios. For monoclonal antibody blocking, NK cell effectors were incubated at room temperature for thirty minutes in the presence of an NKG2D-specific monoclonal

antibody prior to addition of labelled target cells. The percent specific lysis for each effector to target cell ratio was then calculated using % specific lysis = 100 - %survival.

5

Production of Recombinant Proteins

Soluble recombinant versions of the extracellular domain of ULBPs and RAET1E/G were produced as 6-Histidine N-terminal fusions. These were produced as inclusion bodies in *E.coli* BLR (DE3) using vector pT7His derived from pGMT7 (Vales-Gomez et al., (1999) EMBO J. 18, 4250-4260) and the insoluble protein extracted with 6M Guanidine Hydrochloride. Purification and refolding in situ were performed using Ni-NTA resin (Qiagen) by sequential dilution to PBS prior to elution using PBS plus 250mM imidazole. NKG2D-Fc fusion protein was produced from 293T cells using calcium phosphate transfection. The fusion was C-terminal to human IgG1 hinge-CH2-CH3 domains, in pCDNA3.0. UL16 Fc fusion was produced in SignalpIgplus (Sigma) as a fusion N-terminal to human IgG1 CH2-CH3. The recombinant proteins were purified using Protein A Sepharose® (Pharmacia). In all cases, eluted proteins were transferred to PBS by passing through a coarse gel filtration matrix (PD10 column, Pharmacia). SDS-PAGE and western blot analysis verified the integrity of the expressed Fc fusions. The His-tagged protein MW and purity were confirmed by SDS-PAGE, on 12% acrylamide gels based on the protocol of Laemmli. Western blotting was carried out as wet blotting transfer to Immobilon-P membrane (Millipore). Detection was using anti human-Fc HRP conjugated antibody (Dako).

Surface Plasmon Resonance (SPR)

SPR was carried out on a BIACore2000 machine. Running buffer, sensor chips and surface coupling reagents were from BIACore. Anti Human IgG (Dako) was coupled to a CM5 surface using NHS/EDC chemistry. This surface was then used for NKG2D and UL16 binding via the Fc fusion. 1.5µg of NKG2D or UL16-Fc fusion, or a null Fc- fusion control was bound to the anti-IgG followed by sample injection at 20µl/min. Surface regeneration was using 5µl of 10mM HCl. A dilution series of each ULBP was applied over NKG2D, UL16 and Fc control and the level of binding determined. Two separate batches of NKG2D, UL16 and the ULBP/RAET1 proteins were used for each determination and equivalent data obtained for each batch. Kinetic analysis was performed using BIAEvaluation 3.1 software. Separate off rates and combined global fits were performed for each NKG2D ligand dilution series.

RESULTS

RAET1G has a TM region.

Initial analysis the ULBP/RAET cluster called for six expressed genes encoding GPI linked molecules (Radosavljevic et al., (2002) Genomics 79, 114-123). We undertook detailed analysis of these sequences and identified potential TM regions in RAET1E and RAET1G. Further analysis of the genes encoding RAET1E, RAET1G and ULBP2, (RAET1E, RAET1G and RAET1H respectively) revealed a conserved exon structure, where exon 1 encoded the signal peptide and the start of the protein, exons 2 and 3 encompassed the $\alpha 1$ and $\alpha 2$ domains, and exon 4 encoded a hydrophobic sequence. In the ULBP's, this exon encoded the GPI anchor region, and 3' UTR, but in both RAET1G and RAET1E the sequence was compatible with a TM, as well as a short cytoplasmic region (CYT). Exon 5 in RAET1G

encoded the remainder of the putative cytoplasmic domain. The equivalent exon in RAET1H was silent.

To clarify the sequences of the expressed gene products,
 5 we fully sequenced clones corresponding to RAET1E and
 RAET1G (Radosavljevic et al. (2002) Genomics 79, 114-
 123). We confirmed that RAET1G was very similar to ULBP2
 over the first 4 exons. A comparison of the amino acid
 sequence with those of existing murine and human NKG2D
 10 ligands showed that RAET1G was most closely related to
 ULBP2 (85% overall similarity). The highest level of
 amino acid (aa) identity was in the $\alpha 1$ and $\alpha 2$ domains.
 The remaining translated sequence encoded a TM and a
 100aa CYT (Figure 7). Similarly, analysis of the RAET1E
 15 sequence showed that it encodes two α domains then a
 hydrophobic TM followed by a cytoplasmic domain of 20
 amino acids. RAET1E was the most divergent member of the
 cluster, sharing <43% identity with the other ligands,
 whereas ULBPs 1-3 shared ~55-60% identity with each
 20 other. The conserved amino acid sequences were aligned to
 the key structural elements of the $\alpha 1$ and $\alpha 2$ domains by
 performing a ClustalW alignment using the European
 Bioinformatics server (EBI, Hinxton, UK), and subsequent
 comparison to the known crystal structure of ULBP3. The
 25 key structural features of ULBP3 are highlighted in the
 protein sequence alignment (Figure 7).

Like RAET1G, the murine NKG2D ligand MULT1 also had a
 long CYT. No significant sequence similarity was found
 30 between the cytoplasmic regions of the two proteins. The
 cytoplasmic domain of RAET1G did not show homology to any
 proteins or domains when searched by BLAST or through
 Prosite. We searched for known signalling motifs in the
 CYT regions of RAET1E and RAET1G. No classical Immuno-

Tyrosine Inhibitory Motifs (ITIM) or Immuno-Tyrosine Activating Motifs (ITAM) were identified. There was a proline-rich PxPxxP region in the cytoplasmic domain of RAET1G, which corresponded to a consensus SH3- kinase binding motif (Kay et al., (2000) FASEB J. 14, 231-241). Downstream of this were two pairs of hydrophobic residues similar to those attributed to basolateral targetting of MICA (Suemizu et al., (2002) Proc. Natl. Acad. Sci. USA 99, 2971-2976).

10

Figure 6 shows a phylogenetic tree of murine and human ligands. Human and mouse NKG2D are approximately 60% identical, however their ligands are substantially different showing 25-35% identity. Therefore despite showing some similar features, such as GPI anchors or TM regions, substantial duplication and variation has occurred after speciation between mouse and man.

15

Alternative splicing of RAET1G

The sequence of IMAGE clone 2911855 was colinear with RAET1G except for a 100bp deletion, at the start of exon 4. This arrangement is compatible with alternative splicing at this boundary, with a second potential splice start shifted 3' by 100bp. Translation of this deleted form of RAET1G showed that the alternative splicing caused a frame-shift, and premature termination of the protein sequence. This truncated protein is predicted to be soluble, as the frame shift causes termination before the TM region. This splice form is termed RAET1G2, and its alternative sequence ending is shown below that of RAET1G in Figure 7. Exon structures for RAET1G and RAET1G2 are shown in Figure 8.

25

30

Expression patterns of RAET1G/1G2 and RAET1E

Specific PCR primers were designed to establish the expression profiles of RAET1G/1G2 and RAET1E. Several tumour cell lines contained mRNA for RAET1E or RAET1G (Figure 9 and Figure 10) and the genes were expressed independently of each other, in cells of different lineages. This is in contrast to MICA and MICB where expression appears to be restricted to cells of epithelial origin and it is unclear whether they are expressed independently of each other (Bahram et al. (1994) Proc. Natl. Acad. Sci. 91, 6259-6263; Groh et al., (1998) Science 279, 1737-1740). The T cell leukaemia derived line HSB-2 expressed a truncated RAET1G transcript. This cDNA product was cloned using Topo cloning and, when sequenced, was identical to the splice form RAET1G2 in IMAGE clone 2911855. The expression of a splice variant encoding a soluble protein is potentially important given the proposed role of soluble NKG2D ligands in impairment of NK and T cell recognition of tumours (Groh et al., (2002) Nature 419, 734-738). A limited range of normal human tissues tested showed no expression of RAET1E, or the splice form RAET1G2. RAET1G was strongly expressed in colon, but not in other tissues screened (Figure 11). An EST matching RAET1G has also been identified from a larynx cDNA library.

RAET1E and RAET1G expressed on the cell surface bind NKG2D

Full-length cDNA's for RAET1E, RAET1G and ULBP2 were cloned as N-terminal Flag-tagged fusion proteins. These reached the cell surface in transient transfections of CV-1 cells and detection with anti-Flag antibodies in flow cytometry (Figure 12 and Figure 13). NKG2D, expressed as a recombinant soluble Fc fusion protein, bound to COS-7 cells transiently transfected with ULBP2,

RAET1G and RAET1E by flow cytometry (Figure 14 and Figure 15).

RAET1E and RAET1G are capable of inducing NK cell
cytotoxicity via NKG2D

RAET1E and RAET1G expressed in COS-7 cells triggered cytotoxicity by NK cells. NKG2D antibody entirely blocks this activity. Relative killing data for the two ligands and untransfected cells is shown in Figure 16.

Binding interactions of the ULBP family with NKG2D and
UL16

Recombinant soluble versions of ULBP1, ULBP2, ULBP3, RAET1E and RAET1G were analysed for binding to NKG2D by Surface Plasmon Resonance using a BIAcore 2000 machine. Similarly, recombinant ULBP1, RAET1E and RAET1G binding was also measured to UL16. A dilution series of each ULBP protein was passed over NKG2D-Fc, UL16-Fc or Fc fusion control attached to an anti-human IgG surface. Minimal binding was seen to the Fc control surface. Examples of curves used for the kinetic global fit analyses are shown in Figure 17, and the kinetic parameters are shown in Table 1. Table 2 shows the parameters previously determined by others for murine and human ligands (Radaev et al., (2002) J. Immunol. 169, 6279-6285; O'Callaghan et al., (2001) Immunity 15, 201-211; Carayannopoulos et al. (2002) Eur. J. Immunol. 32, 597-605; Carayannopoulos et al. (2002) J. Immunol. 169, 4079-4083).

The data presented in Table 1 were derived from at least two repeat experiments and at least two separate expressions of both Fc fusion and his-tagged proteins. Very little batch to batch variability was seen and all

kinetic and affinity data in Table 1 have been reproduced.

The range of affinities within the complement of human
 5 and murine ligands is comparable and conforms to a similar pattern. The GPI linked murine ligands Rael α - δ have a significantly lower affinity than the ligands with transmembrane domains, H60 and MULT1 (Table 2). Similarly, the three human GPI-anchored ULBP's have lower
 10 affinities for NKG2D than do MICA and the TM-anchored RAET1E and RAET1G molecules.

RAET1E and RAET1G had higher affinities for NKG2D than the other human NKG2D ligands, at 39nM and 356nM
 15 respectively. UL16 bound with varying but high affinity to the three human ligands tested, however RAET1G had a significantly higher affinity for UL16 than either RAET1E or ULBP1, and a faster on-rate, the K_D of 75.6 nM compared to 504 nM and 243 nM respectively.

20 Whilst sharing sequence similarity, the ULBP/RAET1 genes display great diversity of affinity for their shared receptor. It is striking that ULBP2 and RAET1G have 93% amino acid similarity in their α domains yet they bind
 25 NKG2D with 20 fold different affinities. One notable difference between the two is an alanine to proline substitution in RAET1G compared to ULBP2 at position 163, at the start of the helix in the α 2 domains.

30 The presence of soluble MIC in the sera of patients with MIC⁺ tumours has been linked to a reduction in surface NKG2D on lymphocytes and may be a route for immune evasion by impairing the responsiveness of NKG2D bearing NK and T cells (Pende D. et al. (2002) *Cancer Res.* 62

6178-86). MICA is proposed to be lost from the cell surface of tumours through cleavage by metalloproteases (Salih et al., (2002) J. Immunol. 169, 4098-4102) and this may be the case for the TM containing ligand RAET1G.

5 The soluble splice form of RAET1G detected in the T-cell leukaemia line HSB-2 could play a similar role.

The expression pattern of the ULBP/RAET genes presented here and in previous studies (Cosman et al., (2001) Immunity 14, 123-133; Pende et al., (2002) Cancer Res. 62, 6178-6186) shows that multiple ligands for NKG2D can be expressed on one target cell. The ligands are also clearly capable of independent expression. The data are consistent with different NKG2D ligands expressed on

15 different tissues. MIC products are generally expressed on epithelial cells. ULBP/RAET1 can be expressed on epithelial cells but are also expressed in cell lines of non-epithelial origin, providing a rationale for roles distinct from MICA/B, for example in immune responses to

20 lymphoid malignancies and viruses that infect lymphocytes. We show that the affinities of the human ULBP/RAET1 proteins for NKG2D are remarkably diverse, but form two groups. In line with murine data, the GPI-anchored proteins have modest to low affinities for

25 NKG2D, whilst the ligands possessing CYT domains, such as RAET1G, have high affinity. High affinity driven by fast on-rates may be important where early signalling of infection is needed, where rapid association with the associating receptor to deal with infected cells is vital

30 to their removal.

RAET1G may be targeted to the basolateral surface, where its fast on-rate and high affinity could make it a good front line indicator of bacterial challenge. In a

polarised cell layer, such as epithelial surfaces in the gut, the differences in anchorage of NKG2D ligands allow differential distribution in the same cell, different possible signalling pathways, and hence differential availability to lymphocytes. The distribution of ligands on a cell could change on bacterial challenge, transformation, or lymphocyte engagement. The relative distribution of NKG2D ligands in distinct tissues and cellular domains may be fundamental to understanding NKG2D-mediated immune recognition.

RAET1G was shown to be a target of UL16, a molecule that is proposed to promote viral immune evasion by blocking NKG2D recognition. Both ULBP1 and RAET1G bound UL16 with higher affinity than for NKG2D, with very fast on rates. RAET1G is the highest affinity binder of UL16 with an association rate ten-fold faster for UL16 than for NKG2D. This would provide an enhanced ability to bind to viral proteins at low concentrations. The very fast on-rate and high affinity of RAET1G for UL16 indicate its potential as a pathogen recognition molecule. The unique CYT tail carried by this molecule provides the potential to transmit signals within the cell to modulate other molecules involved in responses to pathogens. This is the first NKG2D ligand described with evidence of its own signalling capability.

ligand	analyte	Separate k_d (s^{-1})	Joint k_a ($M^{-1}s^{-1}$) ¹⁾	Joint k_d (s^{-1})	Derived K_D (M)
NKG2D	ULBP1	6.9e-3	4.36e3	7.3e-3	1.68 e-6 = 1.68 μ M
NKG2D	ULBP2	3.36e-2	8.8e-3	6.3e-2	7.16e-6 = 7.16 μ M
NKG2D	ULBP3	5e-3	2.35e3	5.37e-3	2.29e-6 = 2.29 μ M
NKG2D	RAET1E	5e-3	7.49e4	2.92e-3	3.9e-8 = 39nM
NKG2D	RAET1G	3e-3	1.05e4	3.74e-3	3.56e-7 = 356nM
UL16	ULBP1	n/d	2.46e3	5.97 e-4	2.43e-7 = 243 nM
UL16	RAET1E	n/d	1.18e4	5.95e-3	5.04e-7 = 504nM
UL16	RAET1G	n/d	1.15e5	8.71e-3	7.56e-8 = 75.6nM

Table 1

Analyte	k_a ($M^{-1}s^{-1}$)	k_d (s^{-1})	K_D	ref
H60	1.96e6	0.044	23 nM	27
Rae1 α	4.2e5	0.24	581 nM	27
Rae1 β	8.2e5	0.31	378nM	27
Rae1 γ	7.1e5	0.30	529nM	27
Rae1 δ	3.7e5	0.38	1.027 μ M	27
H60	2.1e6	0.03	14nM	28
MULT1	3.8e6	5.8e-3	2nM	7
ULBP3	N/a	N/a	4 μ M	41
MICA	4.26e4	0.013	305nM	10
MICA			800nM	13

Table 2

CLAIMS

1. An isolated nucleic acid which encodes a polypeptide which comprises an amino acid sequence having at least 87% sequence similarity to the amino acid sequence of figure 1 or figure 2.
5
2. An isolated nucleic acid according to claim 1, wherein the polypeptide comprises the amino acid sequence of figure 1.
10
3. An isolated nucleic acid according to claim 1 wherein the polypeptide comprises the amino acid sequence of figure 2.
- 15 4. An isolated nucleic acid according to any one of claims 1 to 3 wherein the polypeptide binds to a UL16 and/or a NKG2D receptor.
- 20 5. An isolated nucleic acid according to any of one of claims 1 to 4 having a nucleotide sequence which has least 85% sequence identity with the nucleotide sequence of figure 3 or figure 4.
- 25 6. An isolated nucleic acid according to any of claims 1 to 5 wherein the isolated nucleic acid hybridises with the nucleic acid sequence shown in figure 3 or figure 4 or the complement thereof under stringent conditions.
- 30 7. An isolated polypeptide encoded by the nucleic acid according to any one of the preceding claims.
8. A recombinant vector comprising a nucleic acid according to any one of claims 1 to 6.

9. A host cell comprising a heterologous nucleic acid according to any one of claims 1 to 6 or a vector according to claim 8.

5 10. A host cell according to claim 9 wherein the host cell is a bacterial cell or a eukaryotic cell.

11. A method of producing a RAET1G polypeptide comprising:

- 10 (a) causing expression from nucleic acid which encodes a RAET1G polypeptide according to any one of claims 1 to 6 in a suitable expression system to produce the RAET1G polypeptide recombinantly; and,
(b) testing the recombinantly produced polypeptide for
15 RAET1G activity.

12. An isolated antibody that binds specifically to a RAET1G polypeptide according to claim 7.

20 13. A method of identifying a cancer condition in an individual may comprise;
determining the presence or amount of soluble RAET1G polypeptide in a sample obtained from the individual.

25 14. A method according to claim 13 wherein the soluble RAET1G polypeptide consists of amino acid sequence of Figure 1.

30 15. A method according to claim 13 or claim 14 wherein the presence or amount of the polypeptide is determined by contacting the sample with an antibody according to claim 12.

16. A method of identifying a cancer condition in an individual may comprise;
determining the presence or amount of a nucleic acid encoding a soluble RAET1G polypeptide in a sample
5 obtained from the individual.

17. A method according to claim 16 wherein the nucleic acid comprises the nucleotide sequence of figure 4.

10 18. A method for obtaining and/or identifying a modulator of a RAET1G polypeptide, which method comprises;
(a) bringing into contact a RAET1G polypeptide and a test compound; and
15 (b) determining the interaction of the RAET1G polypeptide with the test compound;

19. A method for obtaining and/or identifying a compound which modulates the interaction of RAET1G with UL16
20 and/or NKG2D, which method comprises;
(a) bringing into contact a RAET1G polypeptide and a UL16 or NKG2D polypeptide in the presence of a test compound; and
(b) determining the interaction between the UL16 or NKG2D
25 polypeptide and the RAET1G polypeptide before and after addition of the test compound.

20. A method according to claim 18 or claim 19 comprising identifying the test compound as a modulator
30 of RAET1G activity.

21. A method according to any one of claims 18 to 20 comprising isolating and/or purifying a test compound.

22. A method according to any one of claims 18 to 21 comprising synthesising and/or manufacturing said test compound.

5 23. A method according to claims 18 to 22 comprising modifying the test compound to optimise the pharmaceutical properties thereof.

10 24. A method according to claims 18 to 23 comprising formulating the test compound in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier.

15 25. A method of producing a pharmaceutical composition comprising formulating an RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid according to any one of claims 1 to 6 or a fragment thereof, or an antibody according to claim 12 in a pharmaceutical composition with a pharmaceutically acceptable excipient,
20 vehicle or carrier.

26. A modulator of RAET1G activity obtained by one of said methods according to any one of claims 18 to 23.

25 27. A modulator of RAET1G activity according to claim 26 comprising a peptide fragment of a RAET1G polypeptide.

28. A RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid according to any one of
30 claims 1 to 6 or a fragment thereof, an antibody according to claim 12 or a modulator according to any one of claim 26 or claim 27 for use in the treatment of a human or animal body.

29. Use of a RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid according to any one of claims 1 to 6 or a fragment thereof, an antibody according to claim 12 or a modulator according to any one of claim 26 or claim 27 in the manufacture of a medicament for the treatment of an individual with a RAET1G mediated condition.

30. Use according to claim 29 wherein the condition is selected from the group consisting of a pathogenic infection, a cancer condition and an immune disorder.

31. A method of treating an individual having a condition mediated by RAET1G, said method comprising administering a RAET1G polypeptide according to claim 7 or fragment thereof, or nucleic acid according to any one of claims 1 to 6 or a fragment thereof, an antibody according to claim 12 or a modulator according to any one of claim 26 or claim 27, to the individual.

32. A method according to claim 31 wherein the condition is selected from the group consisting of a pathogenic infection, a cancer condition, an immune disorder.



MAAAASPAFLRLPLLLLLSSWCRTGLADPHSLCYDITVIPKIRPGPRWCAVQGQVDE
KTFLEHYDCGSKRVTPVSPLGKKLNVTTAWKAQNPVLREVVDILTEQLLDIQLENYIP
KEPLTLQARMSCEQKAEGHSGSWGQPSFDGQIFLLFDSQNRMWTTTHPGPRKMKEKW
ENDKDMTMSFHYISMGDCTGWLEDFLMGMDSTLEPSAGAPPTMFSGTAQPRATATTL
ILCCLLIMCLLICSRHSLTQSHGHHPQSLQPPHPPLLHPTWLLRRVLWSDSYQIAK
RPLSGGHVTRVTLPIIGDDSHSLPCPLALY TINNGAARYSEPLQVSI

Figure 1



MAAAASPAFLRLPLLLLLSSWCRTGLADPHSLCYDITVIPKIRPGPRWCAVQGQVDE
KTFLEHYDCGSKRVTPVSPLGKKLNVTTAWKAQNPVLREVVDILTEQLLDIQLENYIP
KEPLTLQARMSCEQKAEGHGSGSWQPSFDGQIFLLFDSQNRMWTTTHPGPRKMKEKW
ENDKDMTMSFHYISMGDCTGWLEDFLMGMDSTLEPSAGGTV

Figure 2



1 cctgcgagcc gccaggtgat ccacgggctg ggcttcgctt ctgctgtccc ctgcgatcca
61 actccccaat ggcagcggcc gccagccccg cgttccttct acgcctcccg cttctgtctc
121 tgctgtccag ctggtgcagg accgggctgg ccgaccctca ctctctttgc tatgacatca
181 ccgtcatccc taagttcaga cctggaccac ggtggtgtgc ggttcaaggc caggtggatg
241 aaaagacttt tcttcactat gactgtggca gcaagacagt cacaccctgc agtcccctgg
301 ggaagaaact aaatgtcaca acggcctgga aagcacagaa ccagtagctg agagaggtgg
361 tggacatact tacagagcaa ctgcttgaca ttcagctgga gaattacata cccaaggaac
421 ccctcacctt gcaggccagg atgtcttgtg agcagaaagc cgaaggacac ggcagtggat
481 cttggcagct cagtttcgat ggacagatct tcctcctctt tgactcagaa aacagaatgt
541 ggacaacggt tcctcctgga gccagaaaga tgaaagaaaa gtggggagaat gacaaggata
601 tgaccatgtc cttccattac atctcaatgg gagactgcac aggatggctt gaggacttct
661 tgatgggcat ggacagcacc ctggagccaa gtgcaggagc accaccacc atgtcctcag
721 gcacagccca acccagggcc acggccacca ccctcatcct ttgctgcctc ctcatcatgt
781 gtctcctcat atgtccagg cacagtctga cccaaagcca tggccaccac cctcagtccc
841 tgcagcctcc tcctcatcct cccctgcttc atcctacctg gctgctgaga agagtctttt
901 ggagtgcag ctaccaaata gcgaagcgcc ccttgtctgg tggacacgtg actcgctga
961 ctttacctat cattggagac gactcacact cttaccctg ccctcttgcc ttgtatacaa
1021 taaataacgg cgagccagg tattcgagc cactcaggtc tccatatctt gatggttccc
1081 tggggccagc tgtcttttct tccgtcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1141 aaa

Figure 3



1 atggcagcgg ccgccagccc cgcgttcctt ctacgcctcc cgcttctgct cctgctgtcc
61 agctggtgca ggaccgggct ggccgaccct cactctcttt gctatgacat caccgtcatc
121 cctaagttca gacctggacc acggtggtgt gcggttcaag gccaggtgga tgaaaagact
181 tttcttcact atgactgtgg cagcaagaca gtcacacccg tcagtcccct gggaagaaa
241 ctaaattgtca caacggcctg gaaagcacag aaccagtac tgagagaggt ggtggacata
301 cttacagagc aactgcttga cattcagctg gagaattaca tacccaagga acccctcacc
361 ctgcaggcca ggatgtcttg tgagcagaaa gccgaaggac acggcagtgg atcttggcag
421 ctgagtttcg atggacagat cttcctcctc ttgactcag aaaacagaat gtggacaacg
481 gttcatcctg gagccagaaa gatgaaagaa aagtgggaga atgacaagga tatgaccatg
541 tccttccatt acatctcaat gggagactgc acaggatggc ttgaggactt cttgatgggc
601 atggacagca ccctggagcc aagtgcagga ggcacagtct gacccaaagc catggccacc
661 accctcagtc cctgcagcct cctcctcctc ctcccctgct tcctcctacc tggctgctga
721 ggagagtcct ttggagtgc agctaccaa tagcgaagcg ccccttgtct ggtggacacg
781 tgactcgcgt gactttacct atcattggag acgactcaca ctcccttacc tgccctcttg
841 ccttgtatac aataaataac ggcgcagcca ggtattcgga gccactacag gtctccatat
901 cttgatgggt ccctgggccc agctgtcttt tcttccgtc

Figure 4






Figure 5




Figure 6



Raet1g -MAAASPALRLPLL-LLLSSWCRTGLADPHSLCYDITVIPKIRPGPRWCAGQGVDEK 58
 ulbp2 MAAAAATKILLCLPLL-LLLSGWSRAGRADPHSLCYDITVIPKFRPGPRWCAGQGVDEK 59
 Raet1e -MRRISLTSSPVRLLLFLLLLIALEIMVGSHSLCFNFTIKSLSRPGQPWCEAQVFLKN 59
 ulbp3 MAAAASPAILPRLAILPYLLFDWSGTGRADAHSLWYNFTIIHLPRHQQWCEVQSQVDQK 60

Raet1g TFLHYDCGSKRVTVPSPGLGKLNVTAWKAQNPVLREVVDILTEQLLDIQLENYIPKEPL 118
 ulbp2 TFLHYDCGNKTVTVPSPGLGKLNVTAWKAQNPVLREVVDILTEQLRDIQLENYTPKEPL 119
 Raet1e LFLQYNSDNNMVKPLGLLGKKVNATSTWGETQTGLGEVGRDLRMLLCDIKPQIKTS-DPS 118
 ulbp3 NFLSYDCGSDKVLSMGHLEEQLYATDAWGKQLEMLREVVGQRLRLLELADTELEDFTPSGPL 120

Raet1g TLQARMSCEQKAEHGGSGSWQPSFDGQIFLLEDSONRMWTTTHPGPRKMKEKWENDKDMT 178
 ulbp2 TLQARMSCEQKAEHSSGSWQSFSDGQIFLLEDSEKRMWTTVHPGARKMKEKWENDKVVA 179
 Raet1e TLQVEMFCQHEAERCTGASWQFTINGEKSLFDAMNMTWTVINHEASKIKETWKKDRGLE 178
 ulbp3 TLQVRMSCECEADGYIRGSWQSFSDGKFLLEDSSNNRKWTVVHAGARRMKEKWEKDSGLT 180

[Raet1g alternative splice ending SAGTV]
 Raet1g MSFHYISMGDCTGWLEDFLMGMDSTLEPSAGAPPTMFSGTAQPRATATTLILCCLIMCL 238
 ulbp2 MSFHYFSMGDCIGWLEDFLMGMDSTLEPSAGAPLAMSSGTTQLRATATTLILCCLLIIL- 238
 Raet1e KYFRKLSKGDCHWLREFFLGHWEEAMPEPTVSPVNASDIHWSSSSLPDRWIIIGAFILLVL 238
 ulbp3 TFFKMVSMRDCKSWLRDFLMHRKKRLEPTA--PPTMAPGLAQPKAIAATTLSPWSFLIIL- 237


Raet1g LICSRHSLTQSHGHHPQSLQPPPPHPLLHPTWLLRRVLWSDSYQIAKRPLSGGHVTRVT 297
 ulbp2 PCFILPGI----- 246
 Raet1e MGIVLICVWWQNGEWQAGLWPLRTS----- 263
 ulbp3 CFILPGI----- 244

Raet1g LPIIGDDSHSLPCPLALY TINNGAARYSEPLQVSIS 333

Figure 7



RAET1G



RAET1G2




Figure 8






Figure 9






Figure 10




Figure 11






Figure 12






Figure 13






Figure 14






Figure 15






Figure 16






Figure 17

